6309-59-7

Basic information

• Product Name: Tetrahydrothiopyran-4-one oxiMe
• Synonyms: Tetrahydrothiopyran-4-one oxiMe;NSC 41600;etrahydrothiopyran-4-one oxime;dihydro-2H-thiopyran-4(3H)-one oxime
• CAS NO: 6309-59-7
• Molecular Formula: C₅H₉NOS
• Molecular Weight: 131.19606
• Mol File: 6309-59-7.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 279.4°Cat760mmHg
• Flash Point: 122.8°C
• Appearance: /
• Density: 1.3g/cm³
• Vapor Pressure: 0.00107mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Tetrahydrothiopyran-4-one oxiMe(CAS DataBase Reference)
• NIST Chemistry Reference: Tetrahydrothiopyran-4-one oxiMe(6309-59-7)
• EPA Substance Registry System: Tetrahydrothiopyran-4-one oxiMe(6309-59-7)

Safety Data

• Hazardous Substances Data: 6309-59-7(Hazardous Substances Data)

Usage

General Description

Tetrahydrothiopyran-4-one Oxime is a chemical compound that is often used in the field of organic chemistry for various reactions and synthesis procedures. It is known for its distinct characteristics, often characterized by its carbon-containing ring structure. Tetrahydrothiopyran-4-one oxiMe has a sulfur atom, a nitrogen atom, an oxygen atom, and carbon atoms forming a ring structure, making it a key ingredient in chemical reactions. It's typically used in laboratory settings for research purposes and often plays a crucial role in the development of new compounds. However, like most chemicals, it needs to be handled with caution due to potential health and safety hazards.

InChI:InChI=1/C5H9NOS/c7-6-5-1-3-8-4-2-5/h7H,1-4H2

Upstream product

• 1072-72-6 Tetrahydrothiopyran-4-one 

Downstream Products

• 21926-00-1 4-tetrahydrothiopyranylamine 
• 55118-45-1 Thian-4-on-oxim-p-toluolsulfonat 
• 595597-01-6 1,1-dimethylethyl (1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbamate 
• 210240-20-3 4-aminotetrahydro-2H-thiopyran-1,1-dioxide 
• 273377-07-4 3-fluoro-4-(1,4-thiazepan-4-yl)benzenamine 
• 273377-00-7 benzyl 3-fluoro-4-(1,4-thiazepan-4-yl)phenylcarbamate 
• 1027413-76-8 (S)-5-(aminomethyl)-3-(3-fluoro-4-(1,4-thiazepan-4-yl)phenyl)oxazolidin-2-one 
• 1089669-32-8 N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-thiophenesulfonamide 
• 116529-31-8 1,1-dioxohexahydro-1λ6-thiopyran-4-ylamine hydrochloride 
• 1014612-94-2 4-bromo-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)benzenesulfonamide 
• 943434-47-7 N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide 
• 1187448-70-9 4-(5-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-N-(1,1-dioxotetrahydro-2H-thiopyran-4-yl)benzenesulfonamide 
• 1187448-48-1 4-[2-(1,1-dimethylethyl)-5-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N-(1,1-dioxotetrahydro-2H-thiopyran-4-yl)benzenesulfonamide 

Relevant articles and documents

Evaluating the Viability of Successive Ring-Expansions Based on Amino Acid and Hydroxyacid Side-Chain Insertion

The outcome of ring-expansion reactions based on amino/hydroxyacid side-chain insertion is strongly dependent on ring size. This manuscript, which builds upon our previous work on Successive Ring Expansion (SuRE) methods, details efforts to better define the scope and limitations of these reactions on lactam and β-ketoester ring systems with respect to ring size and additional functionality. The synthetic results provide clear guidelines as to which substrate classes are more likely to be successful and are supported by computational results, using a density functional theory (DFT) approach. Calculating the relative Gibbs free energies of the three isomeric species that are formed reversibly during ring expansion enables the viability of new synthetic reactions to be correctly predicted in most cases. The new synthetic and computational results are expected to support the design of new lactam- and β-ketoester-based ring-expansion reactions.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES

The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.